All In Biotech

Drug Trial Radar · NCT07825389

C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy

Multi-center, Phase 1b/2 Clinical Study of an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy (C-CAR168) for the Treatment of Progressive Multiple Sclerosis Refractory to Standard Therapy

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

119

Planned (sponsor's estimate)

Start

Feb 2027

Primary completion

Feb 2030

Study completion Feb 2030

Sponsor

Lead sponsor
AbelZeta Inc.Industry
Sponsor type
Industry
First posted
Sep 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a global, multicenter, Phase 1b/2 study evaluating the safety and efficacy of C-CAR168, an autologous anti-CD20/BCMA chimeric antigen receptor T-cell therapy, in participants with progressive multiple sclerosis refractory to standard-of-care therapy. The study includes participants with secondary progressive multiple sclerosis (SPMS) and primary progressive multiple sclerosis (PPMS).

Conditions

  • Multiple Sclerosis
  • Primary Progressive Multiple Sclerosis
  • Secondary Progress Multiple Sclerosis (SPMS)
  • Primary Progressive Multiple Sclerosis (PPMS)
  • MS
  • MS (Multiple Sclerosis)
  • Neuro-Degenerative Disease
  • Neuro-Degenerative Diseases
  • Autoimmune

Interventions

  • C-CAR168Drug

    Autologous anti-CD20/BCMA chimeric antigen receptor T-cell therapy administered as a single intravenous infusion following lymphodepleting chemotherapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Severity of Treatment-Emergent Adverse EventsTime frame: Through Month 24
  2. Proportion of Participants With 6-Month Composite Confirmed Disability Progression (6m-cCDP) Through Month 12Time frame: Through Month 12

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Gilbert, Arizona

  • Research Site

    La Jolla, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.